1. Signaling Pathways
  2. Cell Cycle/DNA Damage
    Epigenetics
  3. Aurora Kinase

Aurora Kinase

The Aurora kinases comprise a family of evolutionary conserved serine/threonine kinases (Aurora-A, Aurora-B, and Aurora-C). Aurora kinases control multiple events during cell cycle progression and are essential for mitotic and meiotic bipolar spindle assembly and function.

Aurora-A, Aurora-B, and Aurora-C share a highly conserved kinase domain but have quite different subcellular localizations and functions during mitosis. Aurora-A mostly controls centrosome maturation and bipolar spindle assembly, while Aurora-B and Aurora-C are required for condensation, attachment to kinetochores, and alignment of chromosomes during (pro-)metaphase and cytokinesis. In human tumors, all Aurora kinase members play oncogenic roles related to their mitotic activity and promote cancer cell survival and proliferation. Inhibitors targeting Aurora kinases have attracted attention in cancer research.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-168718
    FAK-IN-22
    Inhibitor
    FAK-IN-22 (Compound 26) is an inhibitor of FAK, JAK3, and Aurora B, with IC50 values of 50.94 nM, 9.99 nM, and 0.49 nM, respectively, effectively inhibiting tumor occurrence and metastasis in pancreatic ductal adenocarcinoma (PDAC). FAK-IN-22 effectively inhibits the proliferation of PANC-1 cells, with an IC50 value of 0.15 μM. FAK-IN-22 induces apoptosis and G2/M phase arrest in PANC-1 cells by inhibiting the FAK/PI3K/Akt signaling pathway.
    FAK-IN-22
  • HY-158618
    Aurora kinase inhibitor-14
    Inhibitor
    Aurora kinase inhibitor-14 (Compound 79) is an orally active and highly selective inhibitor of Aurora kinases with IC50 values of 0.5 nM and 1.2 nM for Aurora A and Aurora B, respectively. Aurora kinase inhibitor-14 binds to the ATP-binding site of Aurora kinases to block chromosome segregation during mitosis and induce apoptosis in tumor cells. Aurora kinase inhibitor-14 is promising for research of various solid tumors and hematological malignancies, such as non-small cell lung cancer, breast cancer, and acute myeloid leukemia.
    Aurora kinase inhibitor-14
  • HY-19565
    KW-2450 tosylate
    Inhibitor
    KW-2450 tosylate is an orally active Aurora A and B kinases, IGF-1R, and IR tyrosine kinases inhibitor. KW-2450 tosylate induces Apoptosis. KW-2450 tosylate also exhibits anticancer activity against triple-negative breast cancer.
    KW-2450 tosylate
  • HY-161407
    AURKA-IN-1
    Inhibitor
    AURKA-IN-1 (compound 9) is an cell-active covalent AURKA inhibitor. AURKA-IN-1 is a lysine-reactive activity probe.
    AURKA-IN-1
  • HY-RS01266
    AURKA Human Pre-designed siRNA Set A
    Inhibitor

    AURKA Human Pre-designed siRNA Set A contains three designed siRNAs for AURKA gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    AURKA Human Pre-designed siRNA Set A
  • HY-149694
    Aurora kinase inhibitor-12
    Inhibitor
    Aurora kinase inhibitor-12 (Compound 1a ) is the inhibitor of aurora kinase which is a key enzyme that is implicated in tumor growth.
    Aurora kinase inhibitor-12
  • HY-115932
    Aurora kinase-IN-1
    Inhibitor
    Aurora kinase-IN-1 (Compound 9) is a potent inhibitor of aurora kinase. Aurora kinase-IN-1 upregulates the expression of G1 cell cycle inhibitory proteins including p21 and p27, and G1 progressive cyclin D1, and downregulates G1-to-S progressive cyclins, resulting in cell cycle arrest at the G1/S boundary. Aurora kinase-IN-1 also induces apoptosis. Aurora kinase-IN-1 is a lead compound for chemotherapeutic agents.
    Aurora kinase-IN-1
  • HY-125158A
    (E/Z)-HOI-07
    Inhibitor
    (E/Z)-HOI-07 is a potent and selective Aurora B inhibitor. HOI-07 has antitumor activity.
    (E/Z)-HOI-07
  • HY-146037
    Aurora A inhibitor 2
    Inhibitor
    Aurora A inhibitor 2 (Compound 16h) is a potent Aurora A kinase inhibitor with an IC50 of 21.94 nM. Aurora A inhibitor 2 induces caspase-dependent apoptosis in MDA-MB-231 cells.
    Aurora A inhibitor 2
  • HY-70044G
    GSK-1070916 (GMP)
    Inhibitor
    GSK-1070916 (GMP) is GSK-1070916 (HY-70044) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. GSK-1070916 is a potent and selective ATP-competitive inhibitor of aurora B and aurora C with Kis of 0.38 and 1.5 nM, respectively, and is >250- fold selective over Aurora A.
    GSK-1070916 (GMP)
  • HY-N12436
    11α-O-Tigloyl-12β-O-acetyltenacigenin B
    11α-O-Tigloyl-12β-O-acetyltenacigenin B is an ester derivative of Tenacigenin B (HY-N1168), which is isolated from Garcinia cambogia (MTC). Tenacigenin B modulates the antitumor effects of Aurora-A in lymphoma.
    11α-O-Tigloyl-12β-O-acetyltenacigenin B
  • HY-RS01275
    AURKC Rat Pre-designed siRNA Set A
    Inhibitor

    AURKC Rat Pre-designed siRNA Set A contains three designed siRNAs for AURKC gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

    AURKC Rat Pre-designed siRNA Set A
  • HY-160691
    GW814408X
    Inhibitor
    GW814408X is a kinase chemical genome group (KCGS) compound that inhibits the AURKC kinase involved in cell cycle progression, checkpoint regulation, and cell division. GW814408X exhibits cell line-dependent toxicity, e.g., cytotoxic effects on HeLa cells. GW814408X acts as a protein kinase inhibitor across ATP-dependent and -independent luciferases with potential implications for Fluc reporter assays.
    GW814408X
  • HY-175830
    PROTAC AURKA degrader 1
    Degrader
    PROTAC AURKA degrader 1 (Compound A16 + X7) is a Aurora kinase A (AURKA) PROTAC degrader. PROTAC AURKA degrader 1 can be used for cancers research. Pink: AURKA ligand (HY-175827); Blue: CRBN ligase ligand (HY-W867704); Black: linker (HY-132208)
    PROTAC AURKA degrader 1
  • HY-RS01273
    AURKC Human Pre-designed siRNA Set A
    Inhibitor

    AURKC Human Pre-designed siRNA Set A contains three designed siRNAs for AURKC gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    AURKC Human Pre-designed siRNA Set A
  • HY-162837
    AURKA against 1
    Inhibitor
    AURKA against 1 is an inhibitor of AURKA (IC50 less than 0.5 nM), targeting endogenous lysine (K162) acetylation, and has anti-proliferation activity against tumor cells. AURKA against 1 induces K162 acetylation, and the kinase activity of AURKA is reversibly restored in HCT116 cells transfected with SIRT3.
    AURKA against 1
  • HY-113894
    Retreversine
    Retreversine is an inactive control for Reversine. Reversine is a novel class of ATP-competitive Aurora kinase inhibitor.
    Retreversine
  • HY-119951
    AKI-001
    Inhibitor
    AKI-001 is an inhibitor of aurora kinase with cellular potency of IC50 of less than 100 nM. AKI-001 shows low nanomolar potency against Aurora A and Aurora B enzymes.
    AKI-001
  • HY-N3737
    Derrone
    Inhibitor
    Derrone, a prenylated isoflavones, is an Aurora kinase inhibitor, with IC50 values of 6 and 22.3 μM against Aurora B and Aurora A, respectively. Derrone shows anti-tumor activity.
    Derrone
  • HY-B0712S1
    Ceftriaxone-13C2,d3 triethylammonium salt
    Inhibitor
    Ceftriaxone-13C2,d3 triethylammonium salt is 13C and deuterated labeled Ceftriaxone (HY-B0712). Ceftriaxone (Ro 13-9904 free acid) is a broad spectrum β-lactam third-generation cephalosporin antibiotic, which has good antibacterial activity against a variety of gram-negative and positive bacteria. Ceftriaxone is a covalent inhibitor of GSK3β with IC50 value of 0.78 mM. Ceftriaxone is an inhibitor of Aurora B. Ceftriaxone has anti-inflammatory, antitumor and antioxidant activities. Ceftriaxone can be used in the study of bacterial infections and meningitis.
    Ceftriaxone-<sup>13</sup>C<sub>2</sub>,d<sub>3</sub> triethylammonium salt
Cat. No. Product Name / Synonyms Application Reactivity

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.